Health Care·Life Sciences Tools & Services·$8.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.00 | N/A | +75.44% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.00 | N/A | +75.44% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook regarding their operational strengths. However, they did not provide specific guidance for the upcoming quarters.
Management highlighted strong performance in their core segments.
They expressed confidence in their product pipeline despite market challenges.
Bio-Techne Corp's strong EPS performance indicates better-than-expected profitability, but the stock's slight decline suggests that investors may have anticipated more comprehensive guidance or revenue details. The lack of revenue information and future guidance may have contributed to the stock's negative reaction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MARATHON PETE CORP
Aug 3, 2020